Literature DB >> 28889108

Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits.

Hanan A Tanash1, Magnus Ekström2, Eva Rönmark3, Anne Lindberg4, Eeva Piitulainen5.   

Abstract

Knowledge about the natural history of severe alpha 1-antitrypsin (AAT) deficiency (PiZZ) is limited. Our aim was to compare the survival of PiZZ individuals with randomly selected controls from the Swedish general population.The PiZZ subjects (n=1585) were selected from the Swedish National AATD Register. The controls (n=5999) were randomly selected from the Swedish population register. Smoking habits were known for all subjects.Median follow-up times for the PiZZ subjects (731 never-smokers) and controls (3179 never-smokers) were 12 and 17 years, respectively (p<0.001). During follow-up, 473 PiZZ subjects (30%), and 747 controls (12%) died. The PiZZ subjects had a significantly shorter survival time than the controls, p<0.001. After adjustment for gender, age, smoking habits and presence of respiratory symptoms, the risk of death was still significantly higher for the PiZZ individuals than for the controls, hazard ratio (HR) 3.2 (95% CI 2.8-3.6; p<0.001). By contrast, the risk of death was not increased in never-smoking PiZZ individuals identified by screening, compared to never-smoking controls, HR 1.2 (95% CI 0.6-2.2).The never-smoking PiZZ individuals identified by screening had a similar life expectancy to the never-smokers in the Swedish general population. Early diagnosis of AAT deficiency is of utmost importance.
Copyright ©ERS 2017.

Entities:  

Mesh:

Year:  2017        PMID: 28889108     DOI: 10.1183/13993003.00198-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  11 in total

Review 1.  Why is Disease Penetration So Variable? Role of Genetic Modifiers of Lung Function in Alpha-1 Antitrypsin Deficiency.

Authors:  Brian D Hobbs; Michael H Cho
Journal:  Chronic Obstr Pulm Dis       Date:  2020-07

2.  Low Prevalence of Mild Alpha-1-Antitrypsin Deficiency in Hospitalized COVID-19-Patients.

Authors:  David Nygren; Ulrica Mölstad; Hans Thulesius; Magnus Hillman; Lars Mikael Broman; Hanan Tanash; Mona Landin-Olsson; Magnus Rasmussen; Maria Thunander
Journal:  Int J Gen Med       Date:  2022-06-28

3.  Decreased Risk of Ischemic Heart Disease in Individuals with Severe Alpha 1-Antitrypsin Deficiency (PiZZ) in Comparison with the General Population.

Authors:  Hanan Tanash; Magnus Ekström; Nawfal Basil; Eva Rönmark; Anne Lindberg; Eeva Piitulainen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-06-04

4.  Lung function and CT lung densitometry in 37- to 39-year-old individuals with alpha-1-antitrypsin deficiency.

Authors:  Behrouz Mostafavi; Sandra Diaz; Eeva Piitulainen; Berend C Stoel; Per Wollmer; Hanan A Tanash
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-11-08

5.  Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43-45 years.

Authors:  Behrouz Mostafavi; Eeva Piitulainen; Hanan A Tanash
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-02-28

Review 6.  Diagnosis and treatment of lung disease associated with alpha one-antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand.

Authors:  Jack Dummer; Claudia C Dobler; Mark Holmes; Daniel Chambers; Ian A Yang; Lianne Parkin; Sheree Smith; Peter Wark; Anouk Dev; Sandra Hodge; Eli Dabscheck; Julian Gooi; Sameh Samuel; Steven Knowles; Anne E Holland
Journal:  Respirology       Date:  2020-02-06       Impact factor: 6.424

7.  Opinions and Attitudes of Pulmonologists About Augmentation Therapy in Patients with Alpha-1 Antitrypsin Deficiency. A Survey of the EARCO Group.

Authors:  Timm Greulich; Anna Albert; Werner Cassel; Tobias Boeselt; Erika Peychev; Andreas Klemmer; Francini Ferreira; Christian Clarenbach; Maria L Torres-Duran; Alice M Turner; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-01-05

8.  The Clinical Utility of Determining the Allelic Background of Mutations Causing Alpha-1 Antitrypsin Deficiency: The Case with the Null Variant Q0(Mattawa)/Q0(Ourém).

Authors:  Judith Bellemare; Nathalie Gaudreault; Kim Valette; Irene Belmonte; Alexa Nuñez; Marc Miravitlles; François Maltais; Yohan Bossé
Journal:  Chronic Obstr Pulm Dis       Date:  2021-01

9.  Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT).

Authors:  Cristina Esquinas; Sonia Serreri; Miriam Barrecheguren; Esther Rodriguez; Alexa Nuñez; Francisco Casas-Maldonado; Ignacio Blanco; Pietro Pirina; Beatriz Lara; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-03-23

10.  Lung transplantation and survival outcomes in patients with oxygen-dependent COPD with regard to their alpha-1 antitrypsin deficiency status.

Authors:  Magnus Ekström; Hanan Tanash
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.